Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Alimera Sciences
December 23, 2015
Psivida eyes uveitis approval
September 29, 2014
After fourth look FDA sees its way clear to approve Alimera’s Iluvien
July 09, 2012
EP Vantage Interview – Genkyotex pockets SFr25m to NOX out diabetic nephropathy
March 05, 2012
Iluvien launch details awaited following Alimera's European win
January 16, 2012
IPO hopefuls line up after woeful 2011
January 06, 2012
Small caps produce clear winners and losers in 2011
November 14, 2011
Alimera and pSivida strike out
October 10, 2011
Event - Alimera and pSivida hope Iluvien will be second time lucky
August 25, 2011
Most valuable unpartnered pipeline assets – what's hot and what's not
April 20, 2011
VC funding for human therapeutics remains depressed
February 04, 2011
Alimera clears some of the muddle on Iluvien data
Load More
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 17, 2023
PD(L)anner – February 2023
February 09, 2023
Biopharma and Medtech Review 2022
Editor's Picks
March 13, 2023
Silicon Valley Bank: biopharma’s latest crisis
March 13, 2023
Pfizer rescues biotech
February 28, 2023
Why Pfizer (and others) will be interested in Seagen
March 04, 2023
ACC 2023 – Esperion’s outcomes win looks lacklustre
March 06, 2023
T-cell receptor behemoths consolidate? Not quite
